Harnessing therapeutic IgE antibodies to re-educate macrophages against cancer

Giulia Pellizzari, Heather J. Bax, Debra H. Josephs, Jelena Gotovina, Erika Jensen-Jarolim, James F. Spicer*, Sophia N. Karagiannis

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

16 Citations (Scopus)
46 Downloads (Pure)


Currently, IgG is the only class of antibodies employed for cancer therapy. However, harnessing of the unique biological properties of a different class, IgE, could engender potent effector cell activation and unleash previously-untapped immune mechanisms against cancer. IgE antibodies are best known for pathogenic roles in allergic diseases and for protective effector functions against parasitic infestation, often mediated by IgE Fc receptor-expressing macrophages. Notably, IgE feature very high affinity for cognate Fc receptors expressed by tumor-associated macrophages (TAMs). Here we review pre-clinical studies that point towards control of cancer growth by tumor antigen-specific IgE that recruit and re-educate TAMs towards activated profiles. Further, we discuss the clinical development harnessing the anti-tumor potential of recombinant IgE antibodies in cancer patients.
Original languageEnglish
Pages (from-to)615-626
Number of pages12
Issue number6
Publication statusPublished - Jun 2020


  • AllergoOncology
  • cancer
  • cancer immunotherapy
  • FcεRI
  • IgE
  • macrophages
  • monocytes
  • tumor-associated macrophage


Dive into the research topics of 'Harnessing therapeutic IgE antibodies to re-educate macrophages against cancer'. Together they form a unique fingerprint.

Cite this